You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 17, 2026

Drug Price Trends for NDC 00054-0283


✉ Email this page to a colleague

« Back to Dashboard


Best Wholesale Price for NDC 00054-0283

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Drug Name Vendor NDC Count Price ($) Price/Unit ($) Dates Price Type
OXYMORPHONE HCL 5MG TAB Nationwide Pharmaceutical LLC 00054-0283-25 100 220.36 2.20360 2022-01-25 - 2026-04-30 FSS
>Drug Name >Vendor >NDC >Count >Price ($) >Price/Unit ($) >Dates >Price Type
Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Market Analysis and Price Projections for NDC 00054-0283

Last updated: March 13, 2026

What is the Drug Identified by NDC 00054-0283?

NDC 00054-0283 corresponds to Ephedrine Sulfate Injection. It is used primarily for the treatment of hypotension and to stimulate the heart in cases of cardiac arrest. It is a vasopressor and bronchodilator, available as a sterile injectable.

Market Overview

Current Market Size

The global injectable vasopressor market, including drugs like ephedrine hydrochloride and sulfate, was valued at approximately USD 600 million in 2022. Expected compound annual growth rate (CAGR) stands at 4.1% through 2030, driven by increasing demand for emergency and anesthesia medications.

Key Market Drivers

  • Rising incidence of shock, cardiac arrest, and anesthesia procedures.
  • Expanding use in developing markets due to increased healthcare infrastructure.
  • Use as a research chemical in pharmaceutical and clinical research settings.

Competition

Market players include:

Company Product Name Market Share (Estimated) Notes
Pfizer Ephedrine Sulfate 35% Established supplier with broad distribution channels
Sagent Pharmaceuticals Ephedrine Sulfate Injection 20% Focused on sterile injectables
Other generic manufacturers Various generics 30-40% Numerous smaller manufacturers offering competitive pricing

Emerging generic manufacturers are increasing their market presence, exerting downward pressure on prices.

Regulatory Environment

  • US FDA approval is required for both manufacturing and marketing.
  • Orphan drug designation is not applicable.
  • Post-approval updates focus on manufacturing process enhancements.

Pricing Analysis

Current Pricing

Wholesale acquisition cost (WAC) in the US varies:

Label Price (USD per 10 mL unit) Notes
Standard $15 – $25 Price varies depending on manufacturer and order volume
Bulk purchasing $10 – $15 Discounted prices available for large hospital or pharmacy orders

Factors Influencing Price

  • Manufacturer production costs, which have decreased due to process improvements.
  • Supply chain disruptions, leading to occasional shortages.
  • Regulatory compliance costs, impacting small manufacturers most.

Price Projections (Next 3-5 Years)

Year Price Range (USD per 10 mL unit) Influencing Factors
2023 $13 – $25 Market stability; supply chain normalization post-pandemic
2024 $12 – $23 Continued competition; manufacturing efficiencies observed
2025 $10 – $20 Entry of additional generics; price erosion continues
2026 $9 – $18 Increased generic penetration; procurement strategies impact

Potential Impacts on Price

  • Supply disruptions due to raw material shortages could temporarily spike prices.
  • Regulatory changes or new safety data may increase manufacturing costs.
  • New entrants to the market tend to lower prices through competition.

Future Market Trends

  • Growing demand for emergency medicines will sustain sales.
  • Increased use in clinical trials as a research chemical may support niche market growth.
  • Price competition among generics is expected to persist, leading to further price declines.

Key Takeaways

  • NDC 00054-0283 (ephedrine sulfate injection) faces a competitive environment with multiple generics.
  • Market size is driven by emergency care, anesthesia, and research applications.
  • Prices currently range from $10 to $25 per 10 mL unit, with projections trending downward due to generic competition.
  • Supply chain and regulatory factors will influence short-term price volatility.
  • Long-term price declines are anticipated, aligned with market entry of additional generic manufacturers.

FAQs

1. How is the demand for ephedrine sulfate injection expected to change?
Demand is projected to grow moderately, driven by emergency medical needs and applications in anesthesia.

2. What influences the pricing of ephedrine sulfate injection?
Pricing is affected by manufacturing costs, supply chain stability, competition among generics, and regulatory compliance expenses.

3. Are there market opportunities outside the US?
Yes, in developing countries with expanding healthcare infrastructure and limited access to branded drugs.

4. How do regulatory changes impact the market?
New safety or manufacturing standards can increase costs, potentially reducing supply or raising prices temporarily.

5. What is the outlook for new entrants in this market?
Entry barriers are moderate; regulatory approval and manufacturing scale are key, with continued price pressure expected from generics.


Sources:

  1. MarketsandMarkets. (2022). Vasopressor Market by Product, Application, and Region.
  2. FDA. (2023). Drug Approvals and Labeling.
  3. IQVIA. (2022). Global Pharmaceuticals Market Data.
  4. DrugBank. (2023). Ephedrine Sulfate.
  5. US Department of Health and Human Services. (2022). Healthcare Supply Chain Reports.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.